Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024 May 15;83(6):752-759.
doi: 10.1136/ard-2023-224771.

2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice

Peter Mandl  1 , Maria Antonietta D'Agostino  2 , Victoria Navarro-Compán  3 , Irina Geßl  4 , Garifallia Sakellariou  5   6 , Abhishek Abhishek  7 , Fabio Becce  8 , Nicola Dalbeth  9 , Hang-Korng Ea  10 , Emilio Filippucci  11 , Hilde Berner Hammer  12   13 , Annamaria Iagnocco  14 , Annette de Thurah  15   16 , Esperanza Naredo  17 , Sebastien Ottaviani  18 , Tristan Pascart  19 , Fernando Pérez-Ruiz  20 , Irene A Pitsillidou  21 , Fabian Proft  22 , Juergen Rech  23   24 , Wolfgang A Schmidt  25 , Luca Maria Sconfienza  26   27 , Lene Terslev  28 , Brigitte Wildner  29 , Pascal Zufferey  30 , Georgios Filippou  31
Affiliations
Practice Guideline

2023 EULAR recommendations on imaging in diagnosis and management of crystal-induced arthropathies in clinical practice

Peter Mandl et al. Ann Rheum Dis. .

Abstract

Objective: To formulate evidence-based recommendations and overarching principles on the use of imaging in the clinical management of crystal-induced arthropathies (CiAs).

Methods: An international task force of 25 rheumatologists, radiologists, methodologists, healthcare professionals and patient research partners from 11 countries was formed according to the EULAR standard operating procedures. Fourteen key questions on the role of imaging in the most common forms of CiA were generated. The CiA assessed included gout, calcium pyrophosphate deposition disease and basic calcium phosphate deposition disease. Imaging modalities included conventional radiography, ultrasound, CT and MRI. Experts applied research evidence obtained from four systematic literature reviews using MEDLINE, EMBASE and CENTRAL. Task force members provided level of agreement (LoA) anonymously by using a Numerical Rating Scale from 0 to 10.

Results: Five overarching principles and 10 recommendations were developed encompassing the role of imaging in various aspects of patient management: making a diagnosis of CiA, monitoring inflammation and damage, predicting outcome, response to treatment, guided interventions and patient education. Overall, the LoA for the recommendations was high (8.46-9.92).

Conclusions: These are the first recommendations that encompass the major forms of CiA and guide the use of common imaging modalities in this disease group in clinical practice.

Keywords: Crystal arthropathies; Magnetic Resonance Imaging; Ultrasonography.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AA has received institutional research grants from AstraZeneca and Oxford Immunotech, royalty from UpToDate and Springer, lecture fees from Cadilla Pharmaceuticals, consulting fees from NGM Bio Limbic and Inflazome, all unrelated to the present work. AI has received honoraria, speaker fees and grants from AbbVie, Alfa-sigma, BMS, Celgene, Celltrion, Eli Lilly, Galapagos, Gilead, Janssen, MSD, Novartis, Pfizer, Sanofi Genzyme and Sobi. FB has received consulting fees from Horizon and has a research agreement with Siemens Healthineers. FP has received grants and personal fees from Novartis, Eli Lilly and UCB, and personal fees from AbbVie, Amgen, BMS, Celgene, Janssen, Hexal, Medscape, MSD, Pfizer and Roche outside the presented work. FP-R has received consulting fees from Arthrosi, Horizon, LG Pharma and Protalix; speaker fees from Horizon and Menarini; research grants from Cruces Rheumatology Association; fees in relation to trial committee or DMSB and Selecta-Sobi; and is on the steering committee of LG Pharma. HBH has received honorary for teaching from AbbVie, UCB, Lilly and Novartis and for participating in advisory boards from AbbVie and Novartis. JR has received unrestricted research grant from Sobi and Novartis, and speaker honoraria and consulting fees from BMS, Novartis and Sobi. LMS has received funding from Esaote SPA, Samsung Medison, GE HealthCare, Pfizer, Abiogen, AbbVie, Janssen-Cilag, Novartis, MSD, Merck Serono, Fidia Farmaceutici, RAW and EchoLight. LT has received speaker fees from Janssen, Novartis, GE and Eli Lilly, and is on the advisory board for UCB and Janssen. MAD'A has received speaker or consultant fees from Novartis, BMS, Janssen, Amgen, Boehringer Ingelheim, AbbVie, AstraZeneca, Pfizer, UCB and Eli Lilly. ND has received consulting fees, speaker fees or grants from AstraZeneca, Novartis, Horizon, Selecta, Arthrosi, JW Pharmaceutical Corporation, PK Med, LG Chem, JPI, PTC Therapeutics, Protalix, Unlocked Labs and Hikma. TP has received honorary from Novartis and research grants from Horizon Pharmaceuticals. VN-C has received consulting fees from AbbVie, Galapagos, Lilly, Novartis, Lilly, Pfizer and UCB, and speaker fees from AbbVie, Fresenius, Lilly, Novartis, Pfizer and UCB.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Neame RL, Carr AJ, Muir K, et al. . UK community prevalence of knee chondrocalcinosis: evidence that correlation with osteoarthritis is through a shared association with osteophyte. Ann Rheum Dis 2003;62:513–8. 10.1136/ard.62.6.513 - DOI - PMC - PubMed
    1. Oliviero F, Scanu A, Galozzi P, et al. . Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. Joint Bone Spine 2013;80:287–90. 10.1016/j.jbspin.2012.08.006 - DOI - PubMed
    1. Zhang W, Doherty M, Bardin T, et al. . European league against rheumatism recommendations for calcium pyrophosphate deposition. Part I: terminology and diagnosis. Ann Rheum Dis 2011;70:563–70. 10.1136/ard.2010.139105 - DOI - PubMed
    1. Schumacher HR. Crystal-induced arthritis: an overview. Am J Med 1996;100:46S–52S. 10.1016/s0002-9343(97)89546-0 - DOI - PubMed
    1. Dalbeth N, Gosling AL, Gaffo A, et al. . Gout. Lancet 2021;397:1843–55. 10.1016/S0140-6736(21)00569-9 - DOI - PubMed

Publication types